Stockscreener 앱 받기
1.42
5.19%
0.07
전일 마감가:
$1.35
열려 있는:
$1.38
하루 거래량:
111.65K
Relative Volume:
0.60
시가총액:
$20.33M
수익:
-
순이익/손실:
$-8.29M
주가수익비율:
-2.0286
EPS:
-0.7
순현금흐름:
$-6.47M
1주 성능:
+6.77%
1개월 성능:
+10.94%
6개월 성능:
-5.02%
1년 성능:
+27.93%
1일 변동 폭
$1.371
$1.42
1주일 범위
$1.30
$1.42
52주 변동 폭
$0.94
$3.59
NanoViricides Inc Stock (NNVC) Company Profile
명칭
NanoViricides Inc
전화
203-937-6137
주소
1 Controls Drive, Shelton, CT
NNVC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.42 | 20.33M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2015-02-11 | 개시 | Midtown Partners | Strong Buy |
NanoViricides Inc 주식(NNVC)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
Nanostructured Drug Market Projected for Significant Expansion by 2032 -Nanoviricides Inc, Ablynx NV, Pfizer - newstrail.com
Small cap wrap: Gunnison Copper, Ocean Power Technologies, NanoViricides... - Proactive Investors
NanoViricides evaluating antiviral drug NV-387 for measles treatment - Proactive financial news
Measles Outbreak Expands Begging for a Drug to Treat the InfectionNanoViricides Declares it is Ready to Fight the Outbreak - Lelezard
NanoViricides, Inc. Appoints Irach Taraporewala as the New CEO and Nominates to Serve as a Member of the Board of Directors - marketscreener.com
Nanostructured Drug Market Detailed In New Research Report 2025 | Nanoviricides Inc., Ablynx NV, Pfizer - newstrail.com
NanoViricides unaffected by US tariff turmoil, says CFO - Proactive financial news
NNVC stock touches 52-week low at $1.02 amid market challenges - Investing.com Canada
NanoViricides unimpacted by tariffs; sees boost by changes at government agencies - Proactive Investors
NNVC stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa
NanoViricides highlights broad-spectrum antiviral strategy and progress with lead drug candidate - Proactive financial news
Virtu Financial LLC Acquires New Position in NanoViricides, Inc. (NYSE:NNVC) - Defense World
Small cap wrap: NanoViricides, G Mining Ventures, Nevis Brands... - Proactive Investors
NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative - Proactive Investors
NanoViricides Has Initiated Bio-analytical Studies as Part of IND-Enabling Safety and Toxicology Studies of Lead Candidate NV-HHV-101 - ACCESS Newswire
NanoViricides (NYSE:NNVC) Trading Up 1.7% – Time to Buy? - Defense World
Stock Update - Investorsobserver
AllPennyStocks.com News: Junior Biotech Bounces off $1; Chart Trying to Turn Bullish - ACCESS Newswire
Market movers: Delta, Kohl's, Asana, NanoViricides... - Proactive Investors
NanoViricides says business unaffected by US tariffs, highlights antiviral pipeline - Proactive financial news
Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments - Marketscreener.com
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company - Jonesboro Sun
Springing into action in time of need: NanoViricides, Inc. (NNVC.OB) - ACCESS Newswire
Unicycive Therapeutics Inc (NASDAQ:UNCY) stock: Is this a flash in the pan today? - US Post News
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan - Lelezard
NanoViricides' NV-387 could provide a crucial missing weapon in the fight against US measles outbreak - Proactive financial news
Investornewsbreaks Nanoviricides (NYSE American: NNVC) Highlights NV-387 As Potential Measles Treatment Amid Outbreak - MENAFN.COM
NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering - ACCESS Newswire
Mpox – a possible US$100mln+ opportunity - Proactive Investors USA
NanoViricides Successfully Completes Required Genetic Toxicology Testing of Lead Drug Candidate NV-HHV-101 - ACCESS Newswire
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am - ACCESS Newswire
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready - ACCESS Newswire
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2020Has Sufficient Cash, Progress on New Coronavirus Drug Program and the Lead HerpeCide(TM) Drug Candidate IND Application - ACCESS Newswire
NanoViricides Receives Cash Infusion of $2.25 Million - ACCESS Newswire
NanoViricides Closes on $8.625 Million Underwritten Public Offering of Common Stock - ACCESS Newswire
NanoViricides Has Initiated Required Safety Pharmacology Assessment of Lead Drug Candidate towards IND - ACCESS Newswire
Small cap headlines: EnWave, NanoViricides, GoviEx, TNR Gold... - Proactive Investors UK
NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials - Proactive Investors USA
NanoViricides, Inc. Has Filed its Quarterly Report - Chronicle-Tribune
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2024 - Marketscreener.com
NanoViricides Inc. (NNVC) reports earnings - Quartz
NanoViricides: Fiscal Q2 Earnings Snapshot - San Antonio Express-News
NanoViricides Inc (NNVC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):